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Introduction 
Inhibitors of Poly-ADP-Ribose Polymerase (PARPi) have been successfully developed and 
approved by FDA for treatment of ovarian cancer carrying mutations in DNA damage response 
(DDR) genes BRCA1/BRCA2[1-3]. In Acute Myeloid Leukemia (AML) patients, these 
mutations are extremely rare. However, chromosomal rearrangements generate chimeric 
oncofusion proteins [4] that, by acting as transcriptional regulators, impair DDR gene 
expression[5, 6]. This prompted us to test the efficacy of using PARPi in AML. 
Materials and Methods 
PARPi were tested in vitro and in vivo. In vitro experiments were carried out in mouse and 
human leukemic cell lines. Mouse leukemic cells expressing the oncofusion gene of interest 
were generated by Retroviral Transduction Transformation Assay (RTTA)[7].   
Results 
Leukemic cells driven by the oncofusion genes, AML1-ETO and PML-RARα, are sensitive to 
PARP inhibition whereas cells harbouring MLL-AF9 translocation are resistant[8]. Treatment 
of AML1-ETO and PML-RARα leukemic cells with PARPi induces apoptosis, senescence, 
cell cycle arrest and differentiation in vitro and significantly prolongs survival in vivo.  By 
using γH2AX and RAD51 as markers of DNA damage and HR (Homologous Recombination) 
we showed that AML1-ETO and PML-RARα cells accumulate DNA damage and are defective 
in recruiting RAD51 to DNA damage foci upon PARPi treatment. Further analysis revealed 
that the expression of a number of genes that are involved in the HR pathway are reduced in 
AML1-ETO and PML-RARα cells including Rad51, Brca2 and Rpa1. This suggests that AML-
ETO and PML-RARα are sensitive to PARPi as result of defective DDR. We showed that 
HOXA9, a key downstream target of MLL-fusions plays a critical role in promoting expression 
of HR genes and thus providing evidence by which MLL-AF9 are resistant to PARPi[9]. 
Depletion of Hoxa9 reduces the expression of Rad51 and Brca2 in MLL-AF9 cells and confers 
PARPi sensitivity in MLL-AF9 leukemic cells, compromising its ability to form colonies, 
repair DNA damage and prolongs survival in mouse models.  Conversely, HOXA9 
overexpression rendered AML1–ETO and PML–RARα cells resistant to PARPi. Likewise, 
pharmacological suppression of Hoxa9, using GSK3 inhibitor LiCl, can also sensitize MLL-
AF9 cells to PARPi and prolongs survival in our mouse model. 
Discussion 
Our data indicate that PARPi might offer a new therapeutic strategy for patients with AML1-
ETO or PML-RARα translocations. More importantly, we showed for the first time that HoxA9 
can activate a potential DNA repair back-up pathway. PARPi in combination with 
pharmacological inhibitors of HOXA9 may represent a novel avenue for tailored therapeutic 
targeting of the aggressive MLL leukaemia[8].  
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